93 POSTER Phase I study of daily oral AZD2171, an inhibitor of the vascular endothelial growth factor receptors (VEGFR), in combination with oxaliplatin and Infusional 5-Fu (mFOLFOX6) in patients with advanced colorectal cancer (CRC): a study of the National Cancer Institute of Canada Clinical Trials GroupE. Chen, Leonard W. Seymour, Sara Mathews et al.|European Journal of Cancer Supplements|2006Cited by 2
719 POSTER Phase I study of AZD2171 in combination with oxaliplatin and infusional 5-FU (mFOLFOX6) in patients (pts) with advanced colorectal cancer (CRC)E. Chen, Lawrence Seymour, Derek J. Jonker et al.|European Journal of Cancer Supplements|2007Cited by 1